Cargando…

Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial

BACKGROUND: Recent studies suggest that vitamin D deficiency represents an additional cofactor of renal anemia, with several mechanisms accounting for this relationship. In line with it, the administration of vitamin D or its analogues has been associated with an improvement of anemia. There are no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riccio, Eleonora, Sabbatini, Massimo, Bruzzese, Dario, Capuano, Ivana, Migliaccio, Silvia, Andreucci, Michele, Pisani, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363688/ https://www.ncbi.nlm.nih.gov/pubmed/25781618 http://dx.doi.org/10.1371/journal.pone.0118174

Ejemplares similares

Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact?
por: Pisani, Antonio, et al.
Publicado: (2018)

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Cardoso, Marilia Mastrocolla de Almeida, et al.
Publicado: (2022)

The potential use of biomarkers in predicting contrast-induced acute kidney injury
por: Andreucci, Michele, et al.
Publicado: (2016)

RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study
por: Riccio, Eleonora, et al.
Publicado: (2022)

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year-Old Girl
por: Bothou, Christina, et al.
Publicado: (2018)

Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis
por: Zhang, Zhuolin, et al.
Publicado: (2021)

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
por: Riccio, Eleonora, et al.
Publicado: (2020)

Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media
por: Michael, Ashour, et al.
Publicado: (2014)

Acute Kidney Injury by Radiographic Contrast Media: Pathogenesis and Prevention
por: Andreucci, Michele, et al.
Publicado: (2014)

Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3–5: Are They Robust? A Fragility Index Analysis
por: Capuano, Ivana, et al.
Publicado: (2022)

Vitamin D Analogues and Coronary Calcification in CKD Stages 3 and 4: A Randomized Controlled Trial of Calcitriol Versus Paricalcitol
por: Anis, Karim H., et al.
Publicado: (2020)

Role of Reactive Oxygen Species in Pathogenesis of Radiocontrast-Induced Nephropathy
por: Pisani, Antonio, et al.
Publicado: (2013)

Chondro/Osteoblastic and Cardiovascular Gene Modulation in Human Artery Smooth Muscle Cells That Calcify in the Presence of Phosphate and Calcitriol or Paricalcitol
por: Shalhoub, V, et al.
Publicado: (2010)

The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials
por: Garofalo, Carlo, et al.
Publicado: (2021)

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
por: Pisani, Antonio, et al.
Publicado: (2015)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Pain in Fabry Disease: Could Spinal Cord Stimulation be a Solution?
por: Buonanno, Pasquale, et al.
Publicado: (2023)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Prevention of Contrast-Induced Nephropathy through a Knowledge of Its Pathogenesis and Risk Factors
por: Andreucci, Michele, et al.
Publicado: (2014)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid and aorta of uremic rats
por: Ritter, Cynthia S., et al.
Publicado: (2015)

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
por: Webb, Nicholas J. A., et al.
Publicado: (2017)

Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence
por: Bae, Eunjin, et al.
Publicado: (2020)

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
por: Riccio, Eleonora, et al.
Publicado: (2020)

Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes
por: Lim, Jeong-Hoon, et al.
Publicado: (2021)

Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
por: Han, Tianzhao, et al.
Publicado: (2013)

Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease
por: de Boer, Ian H., et al.
Publicado: (2012)

Effect of Early and Delayed Commencement of Paricalcitol in Combination with Enalapril on the Progression of Experimental Polycystic Kidney Disease
por: Sagar, Priyanka S., et al.
Publicado: (2021)

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol
por: Riccio, Eleonora, et al.
Publicado: (2021)

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients
por: Izquierdo, María Jesús, et al.
Publicado: (2012)

Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial
por: Panwar, Bhupesh, et al.
Publicado: (2018)

Effects of calcitriol on random skin flap survival in rats
por: Zhou, Kai-liang, et al.
Publicado: (2016)

Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial
por: Larsen, Thomas, et al.
Publicado: (2013)

Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
por: Ussif, Amin, et al.
Publicado: (2018)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b66ovqrj1t1vpim4ki7ng2acnu